Johnson & Johnson (NYSE:JNJ) Shares Acquired by Gitterman Wealth Management LLC

Gitterman Wealth Management LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 10.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 16,596 shares of the company’s stock after buying an additional 1,553 shares during the period. Johnson & Johnson makes up approximately 1.0% of Gitterman Wealth Management LLC’s portfolio, making the stock its 9th largest position. Gitterman Wealth Management LLC’s holdings in Johnson & Johnson were worth $2,400,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Knuff & Co LLC boosted its position in shares of Johnson & Johnson by 0.7% during the 3rd quarter. Knuff & Co LLC now owns 9,466 shares of the company’s stock worth $1,534,000 after purchasing an additional 64 shares during the period. Vertex Planning Partners LLC boosted its position in shares of Johnson & Johnson by 1.3% during the 3rd quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company’s stock worth $844,000 after purchasing an additional 65 shares during the period. Werba Rubin Papier Wealth Management boosted its position in shares of Johnson & Johnson by 3.3% during the 4th quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company’s stock worth $301,000 after purchasing an additional 66 shares during the period. Denali Advisors LLC boosted its position in shares of Johnson & Johnson by 1.3% during the 4th quarter. Denali Advisors LLC now owns 5,128 shares of the company’s stock worth $742,000 after purchasing an additional 67 shares during the period. Finally, Sage Mountain Advisors LLC boosted its position in shares of Johnson & Johnson by 0.5% during the 4th quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company’s stock worth $2,106,000 after purchasing an additional 67 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $162.94 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The firm has a market capitalization of $392.29 billion, a P/E ratio of 24.50, a P/E/G ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company’s fifty day moving average price is $154.98 and its 200 day moving average price is $156.32.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Johnson & Johnson’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the business posted $2.29 earnings per share. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were given a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.04%. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Analyst Ratings Changes

A number of equities analysts recently weighed in on JNJ shares. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Guggenheim reissued a “neutral” rating on shares of Johnson & Johnson in a research report on Monday, March 10th. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Barclays raised their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research report on Tuesday, January 28th. Finally, Bank of America raised their price target on shares of Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a research report on Wednesday, March 5th. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $171.33.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.